Literature DB >> 27922045

Head and neck cancer in 2016: A watershed year for improvements in treatment?

Alain P Algazi1, Jennifer R Grandis2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27922045     DOI： 10.1038/nrclinonc.2016.196

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  8 in total

1.  Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.

Authors:  Tanguy Y Seiwert; Barbara Burtness; Ranee Mehra; Jared Weiss; Raanan Berger; Joseph Paul Eder; Karl Heath; Terrill McClanahan; Jared Lunceford; Christine Gause; Jonathan D Cheng; Laura Q Chow
Journal:  Lancet Oncol       Date:  2016-05-27       Impact factor: 41.316

2.  Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.

Authors:  David I Rosenthal; Paul M Harari; Jordi Giralt; Diana Bell; David Raben; Joyce Liu; Jeltje Schulten; Kian K Ang; James A Bonner
Journal:  J Clin Oncol       Date:  2015-12-28       Impact factor: 44.544

3.  Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial.

Authors:  Stefano Maria Magrini; Michela Buglione; Renzo Corvò; Luigi Pirtoli; Fabiola Paiar; Pietro Ponticelli; Alessia Petrucci; Almalina Bacigalupo; Monica Crociani; Luciana Lastrucci; Stefania Vecchio; Pierluigi Bonomo; Nadia Pasinetti; Luca Triggiani; Roberta Cavagnini; Loredana Costa; Sandro Tonoli; Marta Maddalo; Salvatore Grisanti
Journal:  J Clin Oncol       Date:  2015-12-07       Impact factor: 44.544

4.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

Authors:  James A Bonner; Paul M Harari; Jordi Giralt; Nozar Azarnia; Dong M Shin; Roger B Cohen; Christopher U Jones; Ranjan Sur; David Raben; Jacek Jassem; Roger Ove; Merrill S Kies; Jose Baselga; Hagop Youssoufian; Nadia Amellal; Eric K Rowinsky; K Kian Ang
Journal:  N Engl J Med       Date:  2006-02-09       Impact factor: 91.245

5.  PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer.

Authors:  Hisham Mehanna; Wai-Lup Wong; Christopher C McConkey; Joy K Rahman; Max Robinson; Andrew G J Hartley; Christopher Nutting; Ned Powell; Hoda Al-Booz; Martin Robinson; Elizabeth Junor; Mohammed Rizwanullah; Sandra V von Zeidler; Hulya Wieshmann; Claire Hulme; Alison F Smith; Peter Hall; Janet Dunn
Journal:  N Engl J Med       Date:  2016-03-23       Impact factor: 91.245

6.  Phase 2 Trial of De-intensified Chemoradiation Therapy for Favorable-Risk Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.

Authors:  Bhishamjit S Chera; Robert J Amdur; Joel Tepper; Bahjat Qaqish; Rebecca Green; Shannon L Aumer; Neil Hayes; Jared Weiss; Juneko Grilley-Olson; Adam Zanation; Trevor Hackman; William Funkhouser; Nathan Sheets; Mark Weissler; William Mendenhall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-08-22       Impact factor: 7.038

7.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Authors:  Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

8.  Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.

Authors:  Laura Q M Chow; Robert Haddad; Shilpa Gupta; Amit Mahipal; Ranee Mehra; Makoto Tahara; Raanan Berger; Joseph Paul Eder; Barbara Burtness; Se-Hoon Lee; Bhumsuk Keam; Hyunseok Kang; Kei Muro; Jared Weiss; Ravit Geva; Chia-Chi Lin; Hyun Cheol Chung; Amy Meister; Marisa Dolled-Filhart; Kumudu Pathiraja; Jonathan D Cheng; Tanguy Y Seiwert
Journal:  J Clin Oncol       Date:  2016-09-30       Impact factor: 44.544
  8 in total
  7 in total

1.  Discovery of a potent cytotoxic agent that promotes G2/M phase cell cycle arrest and apoptosis in a malignant human pharyngeal squamous carcinoma cell line.

Authors:  Manunya Nuth; Manjunatha R Benakanakere; Robert P Ricciardi
Journal:  Int J Oncol       Date:  2022-02-25       Impact factor: 5.650

2.  Concurrent chemoradiotherapy using gemcitabine and nedaplatin in recurrent or locally advanced head and neck squamous cell carcinoma.

Authors:  Rui-Xue Huo; Ying-Ying Jin; Yong-Xue Zhuo; Xiao-Tong Ji; Yu Cui; Xiao-Jing Wu; Yi-Jia Wang; Long Zhang; Wen-Hua Zhang; Yu-Mei Cai; Cheng-Cheng Zheng; Rui-Xue Cui; Qian-Ye Wang; Zhen Sun; Feng-Wei Wang
Journal:  World J Clin Cases       Date:  2022-04-16       Impact factor: 1.534

Review 3.  Critical pathways of oral squamous cell carcinoma: molecular biomarker and therapeutic intervention.

Authors:  Sharmistha Dey; Abhay Kumar Singh; Abhinay Kumar Singh; Kartik Rawat; Joyita Banerjee; Vertica Agnihotri; Deepak Upadhaya
Journal:  Med Oncol       Date:  2022-01-20       Impact factor: 3.064

4.  Radiosensitization approaches for HPV-positive and HPV-negative head and neck squamous carcinomas.

Authors:  Rüveyda Dok; Marieke Bamps; Mary Glorieux; Peihua Zhao; Anna Sablina; Sandra Nuyts
Journal:  Int J Cancer       Date:  2019-07-27       Impact factor: 7.396

5.  Methylated genomic loci encoding microRNA as a biomarker panel in tissue and saliva for head and neck squamous cell carcinoma.

Authors:  Yu Cao; Katherine Green; Steve Quattlebaum; Ben Milam; Ling Lu; Dexiang Gao; Hui He; Ningning Li; Liwei Gao; Francis Hall; Matthew Whinery; Elyse Handley; Yi Ma; Tao Xu; Feng Jin; Jing Xiao; Minjie Wei; Derek Smith; Sophia Bornstein; Neil Gross; Dohun Pyeon; John Song; Shi-Long Lu
Journal:  Clin Epigenetics       Date:  2018-04-03       Impact factor: 6.551

6.  Prognostic and clinical implications of c-erbB-2 expression in patients with oral cancer: A meta-analysis.

Authors:  Ying Meng; Peng Yang; Lili Ma
Journal:  Medicine (Baltimore)       Date:  2020-06-05       Impact factor: 1.817

7.  SLUG-related partial epithelial-to-mesenchymal transition is a transcriptomic prognosticator of head and neck cancer survival.

Authors:  Henrik Schinke; Min Pan; Merve Akyol; Jiefu Zhou; Enxian Shi; Gisela Kranz; Darko Libl; Tanja Quadt; Florian Simon; Martin Canis; Philipp Baumeister; Olivier Gires
Journal:  Mol Oncol       Date:  2021-08-21       Impact factor: 6.603
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.